📊 LNTH Key Takeaways
Is Lantheus Holdings, Inc. (LNTH) a Good Investment?
Lantheus demonstrates exceptional financial fundamentals with 61% gross margins, $345M in free cash flow, and a fortress balance sheet (0.52x D/E, 64x interest coverage), making it operationally excellent. However, stagnant growth (0.5% revenue, 0% net income YoY) and sharply declining EPS (-21.8%) signal a mature business with limited expansion catalysts, warranting a neutral stance absent growth visibility.
Fundamentals are strong: high margins (61% gross, 20% operating), robust free cash flow (22% FCF margin), and conservative leverage with ample liquidity and 64x interest coverage. While top-line growth is essentially flat (+0.5% YoY) and diluted EPS declined on share count effects, ROE remains strong at 21% and cash generation is durable. A reacceleration in revenue or sustained margin strength can translate into continued compounding of earnings and FCF from a solid base.
Why Buy Lantheus Holdings, Inc. Stock? LNTH Key Strengths
- Exceptional profitability: 61% gross margin, 15.2% net margin, and 21.4% ROE demonstrate operational excellence and pricing power
- Outstanding cash generation: $345M free cash flow with 22.4% FCF margin provides substantial financial flexibility
- Fortress balance sheet: 0.52x debt-to-equity, 2.7x current ratio, and 64x interest coverage indicate minimal financial risk
- Stable cash-generative business model in essential diagnostic substances sector with recurring revenue characteristics
- High profitability with strong gross/operating margins and ROE/ROA
- Excellent cash conversion and low capex intensity supporting a 22.4% FCF margin
- Healthy balance sheet and liquidity with modest leverage and very high interest coverage
LNTH Stock Risks: Lantheus Holdings, Inc. Investment Risks
- Stagnant growth: 0.5% revenue growth and flat net income YoY suggest market maturity or competitive headwinds
- Deteriorating shareholder returns: 21.8% EPS decline despite stable net income indicates significant share dilution or unfavorable capital allocation
- Lack of growth catalysts: No visible expansion drivers in a mature, commoditized diagnostic market
- Sector cyclicality and dependency on stable healthcare spending patterns with limited pricing flexibility
- Stagnant revenue growth suggesting maturing products or competitive pressure
- EPS dilution from higher share count despite flat net income
- Regulatory and reimbursement exposure typical for diagnostic substances businesses
Key Metrics to Watch
- Revenue growth acceleration and organic growth rate in upcoming quarters
- Share count trends and capital allocation decisions driving EPS divergence from net income
- Operating margin sustainability as company scales free cash flow generation
- New product pipeline development and market expansion initiatives
- YoY revenue growth trajectory
- Diluted shares outstanding trend
Lantheus Holdings, Inc. (LNTH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 22.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.70x current ratio provides a solid financial cushion.
LNTH Profit Margin, ROE & Profitability Analysis
LNTH vs Healthcare Sector: How Lantheus Holdings, Inc. Compares
How Lantheus Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lantheus Holdings, Inc. Stock Overvalued? LNTH Valuation Analysis 2026
Based on fundamental analysis, Lantheus Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lantheus Holdings, Inc. Balance Sheet: LNTH Debt, Cash & Liquidity
LNTH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lantheus Holdings, Inc.'s revenue has grown significantly by 263% over the 5-year period, indicating strong business expansion. The most recent EPS of $4.65 reflects profitable operations.
LNTH Revenue Growth, EPS Growth & YoY Performance
LNTH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $378.7M | $27.8M | $0.41 |
| Q2 2025 | $378.0M | $62.1M | $0.88 |
| Q1 2025 | $370.0M | $72.9M | $1.02 |
| Q3 2024 | $319.9M | -$2.8M | $1.79 |
| Q2 2024 | $321.7M | -$2.8M | $0.88 |
| Q1 2024 | $300.8M | -$2.8M | $-0.04 |
| Q3 2023 | $239.3M | -$2.8M | $0.86 |
| Q2 2023 | $223.7M | -$2.8M | $0.61 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lantheus Holdings, Inc. Dividends, Buybacks & Capital Allocation
LNTH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lantheus Holdings, Inc. (CIK: 0001521036)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LNTH
What is the AI rating for LNTH?
Lantheus Holdings, Inc. (LNTH) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LNTH's key strengths?
Claude: Exceptional profitability: 61% gross margin, 15.2% net margin, and 21.4% ROE demonstrate operational excellence and pricing power. Outstanding cash generation: $345M free cash flow with 22.4% FCF margin provides substantial financial flexibility. ChatGPT: High profitability with strong gross/operating margins and ROE/ROA. Excellent cash conversion and low capex intensity supporting a 22.4% FCF margin.
What are the risks of investing in LNTH?
Claude: Stagnant growth: 0.5% revenue growth and flat net income YoY suggest market maturity or competitive headwinds. Deteriorating shareholder returns: 21.8% EPS decline despite stable net income indicates significant share dilution or unfavorable capital allocation. ChatGPT: Stagnant revenue growth suggesting maturing products or competitive pressure. EPS dilution from higher share count despite flat net income.
What is LNTH's revenue and growth?
Lantheus Holdings, Inc. reported revenue of $1.5B.
Does LNTH pay dividends?
Lantheus Holdings, Inc. pays dividends, with $0.1M distributed to shareholders in the trailing twelve months.
Where can I find LNTH SEC filings?
Official SEC filings for Lantheus Holdings, Inc. (CIK: 0001521036) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LNTH's EPS?
Lantheus Holdings, Inc. has a diluted EPS of $3.41.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LNTH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Lantheus Holdings, Inc. has a BUY rating with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is LNTH stock overvalued or undervalued?
Valuation metrics for LNTH: ROE of 21.4% (sector avg: 15%), net margin of 15.2% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy LNTH stock in 2026?
Our dual AI analysis gives Lantheus Holdings, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is LNTH's free cash flow?
Lantheus Holdings, Inc.'s operating cash flow is $390.1M, with capital expenditures of $45.3M. FCF margin is 22.4%.
How does LNTH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 15.2% (avg: 12%), ROE 21.4% (avg: 15%), current ratio 2.70 (avg: 2).